ArticleReproductive sciences (Thousand Oaks, Calif.)2026
Investigating the Role of ALPK2 in Endometrial Cancer Progression: From Biological Function to Clinical Translation.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Given the limitations of traditional indicators in evaluating the prognosis of endometrial cancer, this study identified the core genes related to prognosis, diagnosis, and treatment within the alpha-protein kinase (ALPK) family to address the lack of research on ALPK family genes in endometrial cancer. Using data from the TCGA database, we combined bioinformatics analyses (Cox regression, Kaplan-Meier analysis, GSVA enrichment, KEGG pathway analysis) and cell experiments (constructing ALPK2 knockdown/overexpression models; conducting clone formation assays; CCK-8 and other experiments), analysis of the associations among gene expression, prognosis, clinicopathological characteristics, and drug sensitivity was conducted. Only ALPK2 was identified as an independent risk factor for poor prognosis of endometrial cancer (HR > 1, P < 0.05). It was highly expressed in tumor tissues (P < 0.01) and associated with high-risk characteristics such as serous subtype and stage III/IV (P < 0.001). ALPK2 promoted tumor progression by regulating core processes such as proliferation and invasion, and pathways including ECM-receptor interaction and PI3K-Akt signaling. Its high expression was associated with resistance to cisplatin and paclitaxel, as well as sensitivity to olaparib (P < 0.01). Moreover, it demonstrated good diagnostic efficacy for stage III with an AUC of 0.872 and showed broad applicability. ALPK2 is a potential key molecule for prognostic assessment, diagnostic accuracy, and targeted therapy of endometrial cancer, providing a new basis for optimizing the diagnosis and treatment of this disease.
Indexed as
Identifiers
42082823What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.